Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

Search

Top

ABSS SOLUTIONS INC Upper Marlboro MD 20772 USA

UEI: SLED_73CE880CE546E13B

ABSS SOLUTIONS INC Upper Marlboro MD 20772 USA is a federal contractor, registered under UEI SLED_73CE880CE546E13B. It has been awarded $11,189,088 across 1 federal contract. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include Army Medical Resources Acq Activity.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_73CE880CE546E13B

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Army Medical Resources Acq Activity$11.2M100%

Awards by NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)$11.2M100%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in ABSS SOLUTIONS INC Upper Marlboro MD 20772 USA's top NAICS codes and agencies

Bridge Contract - Disease Surveillance and Research Support

Solicitation # PANDHA-26-P-0000-047373

Defense Health Agency

POSTED

DEADLINE

Sole Source - Production of ChAdOx-1 and MVA expressing mouse gp70

Solicitation # 75N98026Q00996

The National Cancer Institute intends to award a sole-source, firm fixed price contract under solicitation RFQ 75N98026Q00996 to the Viral Vector Core at the Pandemic Institute, University of Oxford. The project involves the design and production of ChAdOx-1 and MVA viral vectors expressing mouse gp70 and the mouse class II major histocompatibility complex invariant chain. This research is critical for evaluating vaccine efficacy against breast cancer brain metastasis, utilizing proprietary chimpanzee adenovirus technology to avoid pre-existing human adenovirus immunity. The contract falls under NAICS code 541714 for biotechnology research and development and has a performance period of six months from the date of award. Payment terms are set at net 30 days following the acceptance of deliverables. While intended as a sole-source procurement due to the proprietary nature of the technology, the agency will consider capability statements from other interested parties submitted by August 24, 2026.

POSTED

DEADLINE

in about 17 hours

Staffing and Human Resources Support

Army Medical Resources Acq Activity

POSTED

DEADLINE

Medical and WIC-Eligible Supplies Procurement

Army Medical Resources Acq Activity

POSTED

DEADLINE

Travel, Lodging, and OCONUS Logistics Support

Army Medical Resources Acq Activity

POSTED

DEADLINE

IT Systems Support and Cybersecurity for PIMS

Army Medical Resources Acq Activity

POSTED

DEADLINE

Overseas Program Management and Administrative Support

Army Medical Resources Acq Activity

POSTED

DEADLINE

Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)

Solicitation # W911SR-26-R-HEAL

The Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) is a continuous, open solicitation designed to establish a dynamic, pre-qualified network of partners to accelerate the development and fielding of next-generation medical defenses against CBRN threats. Operated by the Capability Program Executive for CBRN Defense (CPE CBRND) under the Department of Defense, this agreement functions as an Indefinite-Delivery Indefinite-Quantity (IDIQ)-like vehicle authorized under 10 U.S.C. §§4021, 4022, and 4023, exempting it from the Competition in Contracting Act of 1984. The program seeks innovative, threat-agnostic host-directed therapeutics that enhance physiological resilience by targeting critical systems such as neurological function, respiratory stability, immune response, hematologic and vascular integrity, and cellular stress and repair pathways. Complementary to this, the government also seeks broad-spectrum therapeutic candidates that can directly neutralize CBRN agents, with emphasis on agents possessing environmental stability, non-cold-chain storage capability, and simplified administration routes like oral, intranasal, or autoinjector formats suitable for immediate use in austere, far-forward operational environments. Interested parties, including MCM developers at any stage from Phase I through FDA licensure and supporting organizations such as CROs, CDMOs, and regulatory experts, must submit a white paper of no more than five pages detailing product mechanisms, efficacy data from validated animal models, regulatory status including IND history and clinical trial results, manufacturing capacity and scale-up plans, and company experience. Collaboration is mandatory, with applicants required to state willingness to team or partner within the PBA ecosystem. Participation requires SAM registration, and all award decisions are based on technical merit and strategic alignment with the program’s mission to build a layered, resilient, and sustainable medical defense portfolio, without fixed deadlines or competitive bidding. The agreement supports the development of dual-use medical solutions with potential applications in civilian critical care, emphasizing ruggedized formulations, clear labeling, durable packaging, and long-term stability to ensure readiness in the most challenging operational conditions. Technical and administrative inquiries should be directed to Hunter Robinson or Alexander Mayatte at the Aberdeen Proving Ground, Maryland office.

POSTED

DEADLINE

Women, Infant, Children Overseas Contract

Solicitation # HT9425-26-R-E004

The Women, Infant, Children (WIC) Overseas Program Support Services contract, solicitation HT9425-26-R-E004, is a performance-based requirement issued by the Army Medical Resources Acquisition Activity for the Department of Defense. The scope of work involves managing and supporting approximately 38 WIC overseas offices at various Outside the Continental United States (OCONUS) sites to provide nutritional and health benefits to members of the Armed Forces, civilian employees, DoD contractors, and their families. Key responsibilities include program management, staffing, operational support, and the maintenance and enhancement of the WIC Information Technology system architecture, specifically the Participant Information Management System (PIMS). The contractor is responsible for providing all necessary personnel, equipment, supplies, and facilities required to perform these non-personal services, ensuring compliance with DHA policies, HIPAA, and cybersecurity standards. This procurement is a 100% 8(a) small business set-aside under NAICS 541611. The contract structure consists of a 12-month base period, which includes a 60-day transition-in phase, followed by four additional 12-month option periods and a 60-day transition-out period. The estimated total contract value ranges from approximately $10,085,640 to $15,185,640, covering labor and various other direct costs such as travel, IT hardware, supplies, and logistics. Evaluation for award will follow a Best Value Trade-off approach, assessing technical approach, program management, key personnel experience, and past performance. Offerors must submit two separate volumes—a technical proposal and a business proposal—via email by the September 18, 2026, deadline. Strict compliance is required regarding Organizational Conflict of Interest (OCI) certifications, security clearance management, and the use of the Procurement Integrated Enterprise Environment (PIEE) for invoicing.

Army Medical Resources Acq Activity

POSTED

DEADLINE

Skin commensal sequencing

Solicitation # 75N98026Q01038

The National Institutes of Health intends to award a non-competitive contract for skin commensal sequencing to SeqCoast Genomic LLC. This procurement, identified by synopsis number 75N98026Q01038, falls under NAICS code 541714 and is being conducted via Simplified Acquisition Procedures for an amount not exceeding 350,000 dollars. The project supports the laboratory of Julie Segre in studying the human skin microbiome by extracting and sequencing genomes of skin commensal organisms to streamline workflows and reduce costs for ongoing research. Interested parties must submit their capabilities, including a technical and cost-price proposal, by August 31, 2026, at 9:00 AM Eastern time. All submissions must be sent electronically to the contracting officer and require an active registration in the System for Award Management. While the government intends to proceed on a non-competitive basis, it will review submitted capability statements to determine if a competitive procurement is necessary.

National Institutes Of Health Olao

POSTED

DEADLINE

Nanobody against NPR-C for growth disorder

Solicitation # 75N98026Q01031

This project focuses on the development of high-affinity and specific VHH nanobodies against human NPR-C to create potential therapeutics for growth disorders like achondroplasia. The scope of work involves two possible development tracks: phage/yeast display using immunized libraries or single B-cell cloning. The process includes antigen generation, alpaca or llama immunization, library construction or B-cell isolation, and rigorous screening and sequencing to identify unique clones. The final goal is to produce and characterize at least 10 unique VHH-Fc candidates with a target affinity of KD=10nM or better, ensuring no cross-reactivity with NPR-B. The project is expected to be completed within four to six months, with deliverables including serum titer reports, sequence data, purified antibodies, and a final summary report. The NIH retains all intellectual property ownership of the resulting antibodies and data. Out of scope activities include humanization, affinity maturation, GMP manufacturing, and stable cell line development. The contract follows a milestone-based payout structure and requires vendors to comply with IACUC-equivalent animal welfare standards.

National Institutes Of Health Olao

POSTED

DEADLINE

Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Solicitation # 75A50126R00001_RFP_NPIVS_27

BARDA is seeking contractors to support the Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program. The selected providers will be responsible for furnishing all necessary personnel, materials, and facilities to produce vaccines, antigens, and adjuvants for pandemic preparedness and public health emergencies. This includes generating and submitting critical analytical, clinical, and manufacturing data to the FDA to ensure rapid regulatory decisions and manufacturing readiness. To be eligible for this award, offerors must have experience producing vaccines against influenza and strains with pandemic potential. Mandatory qualifications include either holding a U.S. influenza vaccine license or demonstrating the development of an influenza vaccine through the submission of a Biologics License Application for seasonal or pandemic vaccines. This solicitation is managed by the Department of Health and Human Services with a response deadline of October 30, 2026.

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

Pre-solicitation Notice: On-Ramp for the Department of Defense OMNIBUS IV Multiple-Award Contract

Solicitation # HT942626RE002

The Defense Health Agency Contracting Activity is preparing to issue an on-ramp to the OMNIBUS IV Multiple Award, Indefinite Delivery, Indefinite Quantity contract vehicle, which supports military medical research and development services across four distinct market segments: medical research and development support, general research and development support, regulatory processes for human and animal research, and translational science services for moving innovations from laboratory to clinical practice. This on-ramp opportunity is exclusively set-aside for small businesses certified under the Small Business Administration’s 8(a) Program, with the aim of expanding the pool of qualified contractors while maintaining alignment with the existing unrestricted contract vehicle. The OMNIBUS IV IDIQ has a cumulative ceiling of $10 billion and has already generated over $600 million in task order awards across 51 task orders since its base period began in 2022, with the majority of activity occurring in fiscal years 2024 through 2026. Task orders are competitively awarded, including set-asides for 8(a) participants, and may be issued by various DoD entities including DHACA, the Naval Supply Systems Command, and the Uniformed Services University of the Health Sciences. The upcoming solicitation, expected to be posted on SAM.gov in late February 2026, follows a delay to align with the February 2026 implementation of the FAR Overhaul, which significantly impacts how small business status is handled under unrestricted IDIQ contracts. Under the new rules, contractors do not need to recertify their small business status at the task order level when bidding on 8(a)-set-aside work, as they may rely on their original IDIQ-level size and status representation—even if they have graduated from the 8(a) Program or grown beyond small business size thresholds. However, contractors must still recertify their status at the IDIQ level within 60 to 120 days prior to the end of the fifth contract year, in compliance with FAR 19.301-2(b)(1)(iii)(A). Proposals must be submitted via the PIEE Solicitation module using a SAM.gov-registered account, and while the initial pre-solicitation notice provides the framework and intent, detailed evaluation criteria, submission instructions, and contract clauses will be formally outlined in the forthcoming RFP. All awards under this on-ramp will be made to small business 8(a) participants, and the government anticipates issuing multiple new contracts

Defense Health Agency

POSTED

DEADLINE

Core Research in Biological Sciences (BIO Core)

Solicitation # 26-517

The National Science Foundation's Directorate for Biological Sciences is offering funding through the Core Research in Biological Sciences solicitation 26-517. This opportunity supports foundational and interdisciplinary research across all biological levels, from molecular to biome scales, encompassing both legacy program topics and new areas of biological science. The program provides single- and multi-investigator awards with flexible budgets and durations to accommodate both small exploratory projects and long-term research commitments. These federal awards are subject to the availability of funds and are managed by the National Science Foundation.

National Science Foundation

POSTED

DEADLINE

in almost 50 years

On-Site Installation and Training ServicesThis subcontract opportunity with the Department of Commerce NIST involves on-site installation, calibration, and training services located in Gaithersburg, Maryland. The scope of work includes system setup and the verification of technical specifications. While these specific services are not mandatory, they will be given additional evaluation consideration if included in the proposal. The project is designated as a total Small Business Set Aside under NAICS code 541714. Interested parties must submit their responses by August 28, 2026, at 1:00 PM. The solicitation was officially posted on August 15, 2026.

Department Of Commerce Nist

POSTED

DEADLINE

Technical Readiness & Prototype DemonstrationThe Technical Readiness and Prototype Demonstration is a subcontract opportunity issued by the Department of Defense under the FA2553 Oprn Testing and Trg Infr Otti Pk agency. The primary objective of this effort is to demonstrate the technical capability to build, test, and deploy software from commercial facilities into government cloud enclaves, ensuring a secure and automated delivery process. This project falls under NAICS code 541714 and will be performed in Colorado Springs. Interested parties must submit their responses by September 4, 2026, following the posting date of August 13, 2026.

FA2553 Oprn Testing & Trg Infr Otti Pk

POSTED

DEADLINE

Established Clinician Investigator Award to Support Mentoring (KS1)The Established Clinician Investigator Award to Support Mentoring (KS1) is a forecast opportunity issued by the National Institutes of Health under the Department of Health and Human Services. This award is designed to provide established clinician investigators with a sustained period of protected time, enabling them to deliver high-quality mentoring and guidance to early-career clinician research scientists. The program is managed by the Division of Biomedical Research Workforce, which serves as the primary point of contact for interested parties. While specific performance locations and set-aside details are not listed, the award aims to strengthen the pipeline of clinician researchers through structured mentorship support.

National Institutes Of Health

POSTED

DEADLINE

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)The National Institute on Aging is issuing a forecast for the Alzheimer's Drug-Development Program to support the pre-clinical and early-stage clinical Phase I development of novel biologic and small-molecule drug candidates. The program aims to identify treatments that prevent Alzheimer's disease, slow its progression, or address cognitive and behavioral symptoms. Funding is available for academic and biotech researchers to conduct development activities internally or through specialized contract research organizations. The initiative focuses on expanding the portfolio of investigational drug candidates for emerging therapeutic targets and diversifying the therapeutic pipeline to support mono-therapy, combination therapy, and precision medicine approaches. This opportunity will utilize the U01 activity code. While applications are not currently being accepted, this notice serves to allow potential applicants time to establish collaborations and design responsive projects.

National Institutes Of Health

POSTED

DEADLINE